NEUCHÂTEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today that A.C.Camargo Cancer Center in Sao Paulo, Brazil has installed Masimo’s noninvasive and continuous hemoglobin (SpHb®) technology to monitor surgical patients.
Clinicians use invasive blood sampling and laboratory analysis of hemoglobin to determine hemoglobin levels and help estimate blood loss to determine need for red blood cell transfusions. However, lab-based hemoglobin is only available intermittently and results are often delayed. SpHb offers real-time visibility to changes – or lack of changes – in hemoglobin between invasive blood sampling.
“The data associating transfusion with higher mortality rates was clear, so we knew we had to implement strategies to reduce transfusions,” said Dr. Eduardo Henrique Joaquim Giroud, anesthesiologist and Director of the Department of Anesthesiology at A.C.Camargo Cancer Center. “This technology enables us to noninvasively and continuously monitor hemoglobin, a strong indicator of blood loss. It provides continuous trend data which, in combination with invasive blood sampling data, helps us determine who actually needs to be transfused and the right amount of blood needed, not more, and not less.”
SpHb monitoring may provide additional insight between invasive blood sampling when:
- The SpHb trend is stable and the clinician may otherwise think hemoglobin is decreasing
- The SpHb trend is rising and the clinician may otherwise think hemoglobin is not increasing fast enough
- The SpHb trend is dropping and the clinician may otherwise think hemoglobin is stable
“For over 60 years, the A.C.Camargo Cancer Center has been serving as an international reference center for prevention, multidisciplinary treatment, teaching and research of cancer,” stated Joe Kiani, Founder and CEO of Masimo. “We are happy to see them adopt SpHb technology through Masimo’s Root® patient monitoring and connectivity platform for the betterment of their patients.”
About A.C.Camargo Cancer Center
A.C.Camargo is a private non-profit institution maintained by Antonio Prudente Foundation and is currently one of the largest integrated cancer centers worldwide. With guided activities on four pillars: prevention, treatment, education and cancer research, they serve private patients and the Unified Health System (SUS). In 2014 alone, it had 3.5 million hospital visits with 62% dedicated to patients of the Unified Health System (SUS). It currently has about 40 medical specialties and more than 4000 professionals engaged with the task of 'combating cancer patient to patient.' In 2014 alone, A.C.Camargo published over 160 articles.
About Masimo
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care – helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that Masimo SET® outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). In the U.S., Masimo rainbow® SET pulse cooximeter instruments and sensors are indicated to provide noninvasive monitoring of arterial oxygen saturation (SpO2) and pulse rate (PR), carboxyhaemoglobin saturation (SpCO®), methaemoglobin saturation (SpMet®), total hemoglobin concentration (g/dl SpHb), and/or respiration rate (RRa®). The devices are not intended to replace laboratory measurements of hemoglobin and have not been cleared by FDA to detect bleeding or reduce the amount or frequency of red blood cell (RBC) transfusions. Additional information about Masimo and its products may be found at www.masimo.com. @MasimoInnovates
Forward-Looking Statements
This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo's unique noninvasive measurement technologies, including: total hemoglobin (SpHb®) contribute to positive clinical outcomes and patient safety; risks related to our belief that Masimo noninvasive medical breakthroughs provide cost-effective solutions with comparable accuracy and unique advantages, including: immediate and continuous results that enable earlier treatment without causing invasive trauma in all patients and in every clinical situation; as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.
Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO, SpMet, PVI are trademarks or registered trademarks of Masimo.